Silodosin
- User: Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Pericoital
- Short-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): TSS Shripad Hegde Kadave Institute of Medical Sciences, Benha University, Recep Tayyip Erdogan University
Details
- API: Silodosin
- Target: α1A-Adrenoceptor
-
Mechanism of Action:
- Inhibition of Sperm Motility
- Inactive Materials: Not Yet Determined
- Regimen: On Demand or 1 Pill/Day
- MPT: Not Potential MPT
- Promising Attributes: Developers intend to create an on-demand or daily use, non-hormonal male method, which may have the potential for fewer side effects.
Product Status
Active/Recent Clinical Research
History
2020: Researchers from TSS Shripad Hegde Kadave Institute of Medical Sciences publish findings that Silodosin, a drug used to treat prostate hypertrophy, could function as a male contraceptive by inducing aspermia and anejaculation. They had 63 men take 8 mg of silodosin 3 hours prior to intercourse and reported no pregnancies.
2025: Researchers from Benha University, with collaboration from University Hospitals Coventry and Warwickshire, publish findings from a prospective placebo controlled study indicating that silodosin is more effective than placebo at sperm suppression and prevention of pregnancy than placebo when taken daily, with an efficacy rate of 96%. In parallel, researchers at Recep Tayyip Erdogan University publish findings of feasibility evaluation in 35 participants, finding total an-ejaculation in the 33 participants who completed follow-up with no impact on orgasm.